Compare TWI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWI | ANNX |
|---|---|---|
| Founded | 1890 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.3M | 730.4M |
| IPO Year | 1997 | 2020 |
| Metric | TWI | ANNX |
|---|---|---|
| Price | $9.92 | $5.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.50 | ★ $16.50 |
| AVG Volume (30 Days) | 551.9K | ★ 1.8M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.93 | $1.29 |
| 52 Week High | $11.70 | $7.18 |
| Indicator | TWI | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 49.35 |
| Support Level | $8.24 | $4.65 |
| Resistance Level | $10.03 | $5.48 |
| Average True Range (ATR) | 0.50 | 0.31 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 19.47 | 57.67 |
Titan International Inc is a manufacturer of wheels, tires, wheel and tire assemblies, and undercarriage systems and components for off-highway vehicles. The company operates through three segments namely Agricultural, Earthmoving/Construction, and Consumer. Geographically, business of the group can be seen in the United States, Europe / CIS, Latin America and Other international. Titan derives majority of the revenue from Agricultural segment which manufacture various agricultural equipment, including tractors, combines, plows, planters and irrigation equipment, and are sold directly to original equipment manufacturers and to the aftermarket through independent distributors, equipment dealers and Titan's own distribution centers.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.